BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ: OVAS) securities in connection to the Company’s January 8, 2015 Secondary Offering. OvaScience investors have until January 22, 2018 to file a lead plaintiff motion.
Investors suffering losses on their OvaScience investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
The complaint filed in this class action alleges that Defendants violated provisions of the Securities Act by issuing false and misleading statements and/or failed to disclose that: (1) the very science behind the Company’s Augment treatment for improved fertility was untested and in doubt; (2) the patients that had received OvaScience’s Augment treatment in 2014 did not achieve a pregnancy success rate that was significantly higher than the rate achieved without the Company’s Augment procedure; (3) the Company had not chosen to undertake its studies outside of the United States, but was forced to as it did not want to meet stringent and expensive federal regulations; and (4) the Company was far from being profitable, or even approaching profitability.
If you purchased shares of OvaScience, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.